A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Alkermes plc
- 30 Aug 2016 Results published in the Journal of Clinical Psychiatry (2016).
- 28 Mar 2016 Data from this trial will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.
- 29 Oct 2015 Results of post-hoc analysis (n=623) published in the International Clinical Psychopharmacology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History